News und Analysen

Fool.com contributor Parkev Tatevosian considers Invitae (NYSE: NVTA) stock and its financial prospects to determine if investors should buy the stock.

*Stock prices used were the afternoon prices

For more crisp and insightful business and economic news, subscribe to The Daily Upside newsletter It's completely free and we guarantee you'll learn something new every day.

As the United

Regeneron Pharmaceuticals (NASDAQ: REGN) has made for a fantastic growth story over the years. From just over $2 billion in revenue in 2013, the company's top line rose to more than $12 billion last

The Food and Drug Administration (FDA) just approved the updated Omicron-adapted COVID-19 booster shots from Moderna (NASDAQ: MRNA) and the COVID-19 booster that Pfizer (NYSE: PFE) and BioNTech

CRISPR Therapeutics (NASDAQ: CRSP) and Bluebird Bio (NASDAQ: BLUE) are at the forefront of developing gene therapies, yet the shares of both companies have underperformed the market over the last 12

You don't have to invest in artificial intelligence or the latest tech company to earn great returns on your investments. The healthcare industry is full of promising investment opportunities of its

Pfizer (NYSE: PFE) is a stock that everyone's familiar with, but that doesn't mean that everyone agrees you should buy it. While its promise of steady returns and a decent dividend might be

Other than running out of money, what economic risk do Intellia Therapeutics, (NASDAQ: NTLA) CRISPR Therapeutics, (NASDAQ: CRSP) Bluebird Bio, (NASDAQ: BLUE) and a bunch of other cutting-edge

It's best not to go all in on high-risk stocks, but that doesn't mean you should avoid them entirely. If you can tolerate some risk, certain players could make a good addition to a diversified

Shares of Scilex (NASDAQ: SCLX) were down more than 14% as of 1 p.m. ET on Monday, despite the company announcing positive phase 2 trial results for its non-opioid pain therapy SP-103. The healthcar

A notable price target cut from an analyst was followed by a dip in the price of DexCom (NASDAQ: DXCM) stock on Friday. Investors traded out of the specialty medical device maker, reducing its value

Shares of ImmunityBio (NASDAQ: IBRX) were up more than 30% for the week as of 10 a.m. ET on Friday, according to data provided by S&P Global Market Intelligence. The clinical-stage biotech's stock

Last year was challenging for the stock market. Things have been better since 2023 started, but some equities have even performed pretty well throughout this ordeal. That's the case with Exelixis

The elite club of Dividend Kings arguably stands out as the market's most prestigious group of dividend payers. Companies must have raised their payouts for at least 50 consecutive years to join, a

Abbott Laboratories (NYSE: ABT) is a leading healthcare company with a global presence. It has a diverse business with four key segments: established pharmaceuticals, diagnostics, nutrition, and

Aclaris Therapeutics (NASDAQ: ACRS) had a fine Thursday, at least as far as its stock was concerned. The biotech's shares enjoyed a nearly 6% lift in price, thanks largely to a generous price-target

Since December 2021, superstar investor Cathie Wood has been adding to her position in genetic-testing company Invitae (NYSE: NVTA) while many investors were doing just the opposite. The stock has

When investing in equities, even a relatively modest initial sum such as $500 can go a long way, provided investors pick the right stocks and continue adding to their positions regularly. Let's

Innovation never sleeps in the healthcare sector. At the beginning of this year, there had never been a vaccine approved by the U.S. Food and Drug Administration (FDA) for the prevention of the

In the earliest days of the coronavirus vaccine race, Novavax (NASDAQ: NVAX) stood out as a potential winner. As a result, investors bet on the company and drove up its share price more than 2,700%

If you're looking for dividend stocks that can provide steady income and growth potential, you might want to consider adding Amgen (NASDAQ: AMGN) and American Express (NYSE: AXP) to your portfolio

The pandemic isn't over -- much as we might wish it were. An ongoing surge in coronavirus cases is pouring cold water on these hopes. We recently got a stark reminder that the disease spares nobody

If you're looking for dividend stocks that offer both attractive yields and strong growth prospects, you might want to consider AbbVie (NYSE: ABBV) and Bristol Myers Squibb (NYSE: BMY). Both of

The hot-streak biotech stock of the moment, CymaBay Therapeutics (NASDAQ: CBAY), again rose in price on Tuesday. That extends the company's winning streak on the market following the impressive